Each chewable tablet contains:
Montelukast (as sodium) 5mg
Levocetirizine dihydrochloride 2.5mg
Each chewable tablet contains:
Montelukast (as sodium) 5mg
Levocetirizine dihydrochloride 5mg
MONTELUKAST PLUS LEVOCETIRIZINE is indicated for the relief of symptoms associated with seasonal and perennial allergic rhinitis.
MONTELUKAST PLUS LEVOCETIRIZINE is contraindicated in patients with a known hypersensitivity to Montelukast or Levocetirizine, patients with severe renal (creatinine clearance less than 10 ml/min) or hepatic impairment, and in children 6-11 years of age with renal impairment.
DOSAGE AND ADMINSTRATION
Patients with hepatic disease
No dosage adjustment is needed in patients solely with mild to moderate hepatic impairment. Usage is not recommended in patients with severe hepatic impairment.
Children and Adolescents
Children aged 6 – 14 : one chewable tablet containing 5mg Montelukast and 2.5mg Levocetirizine or 5mg Montelukast and 5mg Levocetirizine once daily
Or as prescribed by the physician.
The cysteinyl leukotrienes (LTC4, LTD4, and LTE4) are potent inflammatory eicosanoids released from various cells including mast cells and eosinophils. These important mediators bind to cysteinyl leukotriene receptors. Cysteinyl leukotrienes have been correlated with the pathophysiology of asthma and allergic rhinitis. In asthma, leukotriene-mediated effects include bronchoconstriction, mucous secretion, vascular permeability, and eosinophil recruitment. In allergic rhinitis, cysteinyl leukotrienes are released from the nasal mucosa after allergen exposure during both early- and late-phase reactions and are associated with symptoms of allergic rhinitis. Intranasal challenge with cysteinyl leukotrienes has been shown to increase nasal airway resistance and symptoms of nasal obstruction. Montelukast is an orally active compound which binds with high affinity and selectivity to the cysteinyl leukotriene type 1 receptor thereby preventing cysteinyl leukotrienes from exerting their affects.
Levocetirizine, the active enantiomer of cetirizine, is anti-histamine. Its principal effects are mediated via selective inhibition of H1 receptors. The antihistamine activity of Levocetirizine has been documented in a variety of animal and human models.
Montelukast is rapidly 2 to 4 hours absorbed following oral administration. Mean peak plasma concentration (Cmax) is achieved 3 hours (Tmax) after administration of a 10mg dose in adults in the fasted state. The mean oral bioavailability is 64%. The oral bioavailability and Cmax are not influenced by a standard meal. Safety and efficacy were demonstrated in clinical trials where the 10-mg film-coated tablet was administered without regard to the timing of food ingestion. Cmax is achieved in 2 hours after administration of the 5mg chewable tablet in adults in the fasted state. The mean oral bioavailability is 73% and is decreased to 63% by a standard meal.
Montelukast is more than 99% bound to plasma proteins. Steady-state volume of distribution of Montelukast averages 8 -11 liters. Studies in rats with radio labeled montelukast indicate minimal distribution across the blood-brain barrier. In addition, concentrations of radio labeled material at 24 hours post dose were minimal in all other tissues.
Montelukast is extensively metabolized. In studies with therapeutic doses, plasma concentrations of metabolites of Montelukast are undetectable at steady state in adults and children. In vitro studies using human liver microsomes indicate that cytochrome P450 3A4, 2A6 and 2C9 are involved in the metabolism of Montelukast. Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of Montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6. The contribution of metabolites to the therapeutic effect of montelukast is minimal.
The plasma clearance of Montelukast averages 45 ml/min in healthy adults. Following an oral dose of radio labeled Montelukast, 86% of the radioactivity was recovered in 5-day fecal collections and <0.2% was recovered in urine. Coupled with estimates of Montelukast oral bioavailability, this indicates that Montelukast and its metabolites are excreted almost exclusively via the bile.
Patients with Hepatic Impairment
Patients with mild-to-moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of Montelukast resulting in 41% (90% CI=7%, 85%) higher mean Montelukast area under the plasma concentration curve (AUC) following a single 10-mg dose. The elimination of Montelukast was slightly prolonged compared with that in healthy subjects (mean half-life, 7.4 hours). No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency. The pharmacokinetics of Montelukast in patients with more severe hepatic impairment or with hepatitis has not been evaluated.
Levocetirizine is rapidly and extensively absorbed following oral administration. Peak plasma concentrations are achieved 0.9 h after dosing. Steady state is achieved after two days. Peak concentrations are 270 ng/ml and 308 ng/ml following a single and a repeated 5 mg dose once daily, respectively. The extent of absorption is dose-independent and is not altered by food, but the peak concentration is reduced and delayed.
No tissue distribution data are available in humans, neither concerning the passage of Levocetirizine through the blood-brain-barrier. In rats and dogs, the highest tissue levels are found in liver and kidneys, the lowest in the CNS compartment. Levocetirizine is 90% bound to plasma proteins. The distribution of Levocetirizine is restrictive, as the volume of distribution is 0.4 l/kg.
The extent of metabolism of Levocetirizine in humans is less than 14% of the dose and therefore differences resulting from genetic polymorphism or concomitant intake of enzyme inhibitors are expected to be negligible. Metabolic pathways include aromatic oxidation, N- and O- dealkylation and taurine conjugation. Dealkylation pathways are primarily mediated by CYP 3A4 while aromatic oxidation involved multiple and/or unidentified CYP isoforms. Levocetirizine had no effect on the activities of CYP isoenzymes 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 at concentrations well above peak concentrations achieved following a 5 mg oral dose. Due to its low metabolism and absence of metabolic inhibition potential, the interaction of Levocetirizine with other substances, or vice-versa, is unlikely.
The plasma half-life in adults is 7.9 ± 1.9 hours. The mean apparent total body clearance is 0.63 ml/min/kg. The major route of excretion of Levocetirizine and metabolites is via urine, accounting for a mean of 85.4% of the dose. Excretion via feces accounts for only 12.9% of the dose. Levocetirizine is excreted both by glomerular filtration and active tubular secretion.
Patients with Hepatic Impairment
Levocetirizine has not been studied in patients with hepatic impairment. The non-renal clearance (indicative of hepatic contribution) was found to constitute about 28% of the total body clearance in healthy adult subjects after oral administration. As Levocetirizine is mainly excreted unchanged by the kidney, it is unlikely that the clearance of Levocetirizine is significantly decreased in patients solely with hepatic impairment.
In children 6-11 years of age, Cmax and AUC values are about 2-fold greater than normal healthy adults when given the same dose (5mg once daily). Cmax occurred 1.2 hours post dose in children, total body clearance was 30% greater and the elimination half-life 24% shorter than adults.
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
The administration of Levocetirizine to infants and toddlers aged less than 2 years is not recommended. Therefore the use of MONTELUKAST PLUS LEVOCETIRIZINE is not recommended in infants and toddlers less than 2 years of age. In sensitive patients the simultaneous administration of cetirizine or Levocetirizine and alcohol or other CNS depressants may have effects on the central nervous system, although it has been shown that the racemate cetirizine does not potentiate the effect of alcohol. Comparative clinical trials have revealed no evidence that Levocetirizine at the recommended dose impairs mental alertness, reactivity or the ability to drive. Nevertheless, some patients do experience somnolence, fatigue and asthenia under therapy with Levocetirizine. Therefore, patients intending to drive, engage in potentially hazardous activities or operate machinery should take their response to the medicinal product into account.
In drug-interactions studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (ethinyl estradiol/ norethindrone 35/1), terfenadine, digoxin and warfarin. The area under the plasma concentration curve (AUC) for Montelukast was decreased approximately 40% in subjects with co-administration of phenobarbital. Since Montelukast is metabolised by CYP 3A4, caution should be exercised, particularly in children, when Montelukast is coadministered with inducers of CYP 3A4, such as phenytoin, phenobarbital and rifampicin. In vitro studies have shown that Montelukast is a potent inhibitor of CYP 2C8. However, data from a clinical drug-drug interaction study involving Montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP 2C8) demonstrated that Montelukast does not inhibit CYP 2C8 in vivo. Therefore, Montelukast is not anticipated to markedly alter the metabolism of drugs metabolized by this enzyme (e.g., paclitaxel, rosiglitazone, and repaglinide.)
In vitro data indicate that levocetirizine is unlikely to produce pharmacokinetic interactions through inhibition or induction of liver drug-metabolizing enzymes. No in-vivo drug-drug interaction studies have been performed with Levocetirizine. In pharmacokinetic interaction studies performed with racemic cetirizine, cetirizine did not interact with antipyrine, pseuoephedrine, erythromycin, azithromycin, ketaconazole or cimetidine. A small decrease in the clearance of cetirizine was caused by a 400mg dose of theophylline. Ritonavir increased the plasma AUC, half life and decreased the clearance 42%, 53% and 29% respectively. The disposition of retinovir was not altered by administration of cetirizine.
Montelukast has been evaluated for safety in approximately 2950 adult and adolescent patients 15 years of age and older in clinical trials. In placebo-controlled clinical trials, the following adverse experiences reported with montelukast (M) occurred in greater than or equal to 1% of patients and at an incidence greater than that in patients treated with placebo (P), regardless of causality assessment; Body As A Whole; Asthenia / fatigue M (1.8%), P (1.2%). Fever: M (0.6%), P (3.0%). Abdominal Pain: M (2.9%), P (2.5%) Trauma: M (1.0%), P (0.8%). Digestive System Disorders: Dyspepsia M (2.1%), P (1.1%). Infectious gastroenteritis: M (2.1%), P (1.1%). Dental Pain: M (1.7%), P (1.0%). Nervous System / Psychiatric: Dizziness M (1.9%), P (1.4%). Headache: M (18.4%), P (18.1%). Respiratory System Disorders: Congestion, nasal M (1.6%), P (1.3%). Cough M (2.7%), P (2.4%). Influenza: M (4.2%), P (3.9%). Skin/Skin Appendages Disorder; Rash M (1.6%), P (1.2%). Laboratory Adverse Experiences;* ALT increased M (2.1%), P (2.0%). AST increased M (1.6%), P (1.2%). Pyuria: M (1.0%), P (0.9%).
In therapeutic studies in women and men aged 12 to 71 years, 15.1% of the patients in the Levocetirizine 5 mg group had at least one adverse drug reaction compared to 11.3% in the placebo group. 91.6 % of these adverse drug reactions were mild to moderate.
In therapeutic trials, the drop out rate due to adverse events was 1.0% (9/935) with Levocetirizine 5 mg and 1.8% (14/771) with placebo. Clinical therapeutic trials with Levocetirizine included 935 subjects exposed to the drug at the recommended dose of 5 mg daily. From this data, the following adverse drug reactions were reported at rates of 1 % or greater during treatment with Levocetirizine 5 mg (L) or placebo (P); Headache: L (2.6%), P (3.2%). Somnolence: L (5.2%), P (1.4%). Dry Mouth: L (2.6%), P (1.6%). Fatigue: L (2.5%), P (1.2%). Further uncommon incidences of adverse reactions like asthenia or abdominal pain were observed. The incidence of sedating adverse drug reactions such as somnolence, fatigue, and asthenia was altogether more common (8.1 %) with Levocetirizine 5 mg than with placebo (3.1%). In addition to the adverse reactions reported during clinical studies and listed above, very rare cases of the following adverse drug reactions have been reported in post-marketing experience; Immune system disorders: hypersensitivity including anaphylaxis. Psychiatric disorders: aggression, agitation. Nervous system disorders: convulsion. Eye disorders: visual disturbances. Cardiac disorders: palpitations. Respiratory, thoracic, and mediastinal disorders: dyspnea. Gastrointestinal disorders: nausea. Hepatobiliary disorders: hepatitis. Skin and subcutaneous tissue disorders: angioneurotic edema, fixed drug eruption, pruritus, rash, urticaria. Musculoskeletal, connective tissues, and bone disorders: myalgia. Investigations: weight gain, abnormal liver function tests.
Foods, Drugs, Devices and Cosmetics Act prohibits dispensing without a prescription.
STORE AT TEMPERATURES NOT EXCEEDING 30OC
Montelukast sodium + Levocetirizine dihydrochloride (Co-Altria Ped) 5mg/2.5mg Chewable Tablet X Alu-alu blister pack of 10’s, box of 30 chewable tablets
Montelukast sodium + Levocetirizine dihydrochloride (Co-Altria Ped) 5mg/5mg Chewable Tablet X Alu-alu blister pack of 10’s, box of 30 chewable tablets